OXFORD, UK - Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, today announced that it has appointed Dr Ian J Smith to the position of Chief Executive Officer.
Dr Smith has nearly 30 years’ experience in the drug delivery industry. Previously, he has led the inhalation and device product development groups at both Glaxo and Pfizer. He was also Head of Medical Device Development at PA Consulting and R&D Director at Andaris. In 2001, he founded drug delivery company Meridica and led the organization as CEO until 2004, when it was acquired by Pfizer and valued at $140 million. Most recently, Dr Smith was Director of H12 Consulting, which provides strategic advice to industry and investors on drug delivery technologies.
“We are delighted to welcome Ian to Glide Pharma,” said Mark Kirby, Glide Pharma’s Chairman. “His extensive experience in the drug delivery industry, both developing innovative new products and building successful companies, will be a great asset as Glide progresses its solid dose injector technology to market. I would also like to take this opportunity to thank James Otter for his dedication and commitment in leading the company previously, and look forward to his continuing input as a member of the Glide Pharma Board.”
“I am very pleased to be joining Glide Pharma at this exciting time in the company’s development,” said Dr Ian Smith, Glide Pharma’s CEO. “Having spent many years in the industry, I have keenly observed the progress of Glide’s unique solid dose needle-free technology, and I now look forward to playing a key role in accelerating its advance towards commercialisation.”
